BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15034544)

  • 1. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.
    Lemieux B; Tartas S; Traulle C; Espinouse D; Thieblemont C; Bouafia F; Alhusein Q; Antal D; Salles G; Coiffier B
    Bone Marrow Transplant; 2004 May; 33(9):921-3. PubMed ID: 15034544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
    Naparstek E
    Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
    Shortt J; Spencer A
    Bone Marrow Transplant; 2006 Sep; 38(6):433-6. PubMed ID: 16892074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
    Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?
    Rodriguez J
    Nat Clin Pract Oncol; 2005 Feb; 2(2):74-5. PubMed ID: 16264876
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
    Nomura S; Ishii K; Kamitsuji Y; Uoshima N; Ishikawa E; Kitayama H; Hayashi K
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):206-12. PubMed ID: 17456632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
    Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
    Leonard JP; Link BK; Emmanouilides C; Gregory SA; Weisdorf D; Andrey J; Hainsworth J; Sparano JA; Tsai DE; Horning S; Krieg AM; Weiner GJ
    Clin Cancer Res; 2007 Oct; 13(20):6168-74. PubMed ID: 17947483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
    Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.